Advanced Therapies Integrates 2022 Track 1

CELLULAR GROWTH

How do you secure VC investment? This track focuses on how to develop and present your advanced therapy innovation to secure investment.

Welcome and opening remarks

MATTHEW DURDY | Chief Executive Officer | Cell and Gene Therapy Catapult

Fireside Chat

An interview with: 

MARTIN MURPHY | Chief Executive Officer | Syncona Investment Management Limited

Interviewed by: 

MATTHEW DURDY | Chief Executive Officer | Cell and Gene Therapy Catapult

Fireside Chat

An interview with: 

NICOLA REDFERN | Consultant | NJ Redfern Ltd

Interviewed by: 

MATTHEW DURDY | Chief Executive Officer | Cell and Gene Therapy Catapult

Viable cells to viable sells

How do you develop an investible opportunity that is commercially viable?

FACILITATED BY

Mike Lyne | Translational Research Management Lead | NIHR Biomedical Research Centre

PANELLISTS

Joe Healey | Chief Executive Officer and Co-Founder | NanoSyrinx
Jason Mellad | Chief Executive Officer | Start Codon
Stefanos Theoharis | Independent Expert | Former Bone Therapeutics SA
Mustafa Munye | Director of R&D Operations | Complement Therapeutics
Catriona Crombie | Associate Director: Technology Transfer and Philanthropic Fund Manager | LifeArc

Pitch perfect: advancing therapies

How to present an investible opportunity, focusing on pitching, partnering and funding opportunities.

FACILITATED BY

Sam Goldsmith | Senior Commercialisation of Research Manager | Cell and Gene Therapy Catapult

PANELLISTS

Jenny Laird | Vice President, Search & Evaluation Pain & Neurodegeneration | Eli Lilly and Company
Moin Saleem | Professor of Paediatric Renal Medicine | University of Bristol
Raj Mehta | Entrepreneur in Residence | Apple Tree Partners
Kerstin Papenfuss | Associate Director Therapeutics | Deep Science Ventures
Marcelo Bravo | Co Founder & Chief Executive Officer | OXVax

 

VC judges: what is the X factor?

What are VC Investors looking for at different stages of the life cycle? How is the current economic environment impacting Venture Capital?

FACILITATED BY

Nathan Sigworth | Co-founder and Chief Executive Officer | CCX

PANELLISTS

Freddie Dear | Head of Corporate Development & Portfolio Manager | Ascend Gene and Cell Therapies
Eric Halioua | President & Chief Executive Officer | PDC*line Pharma
Oliver Sexton | Investment Director | UKI2S
Dominic Schmidt | General Partner | Advent Life Sciences
Chris Baker | Investment Principal | LifeArc Ventures
Karolina Zapadka | Investor | Parkwalk Advisors

Healthy Economics for thriving ATMPs

How do you plan ATMP Health Economics for early-stage R&D, ensuring commercial viability?

FACILITATED BY

Panos Kefalas | Director of the Access Strategy Group | Cell and Gene Therapy Catapult

PANELLISTS

Simon Chandler | Chief Executive Officer | Rinri Therapeutics
Kirsty Wydenbach | Head of Regulatory Strategy | Weatherden
Paul Catchpole | Value & Access Policy Director | Association of the British Pharmaceutical Industry (ABPI)
Steve Kappenthuler | Chief Business Officer and Co-founder | Muvon Therapeutics
Laura Beswick | Head of Health Economics and Market Access | Cell and Gene Therapy Catapult